Usability of the Foresee Home in Intermediate Age Related Macular Degeneration (AMD) Patients
NCT ID: NCT00748384
Last Updated: 2013-05-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2009-02-28
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Foresee Home for Monitoring Age Related Macular Degeneration (AMD)
NCT01010997
Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age Related Macular Degeneration
NCT01334294
Age-Related Macular Degeneration (AMD) - Usability Study
NCT00963339
Comparison Between Foresee Home and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)
NCT01073592
Correlation Between Visual Field Defects on FORESEE HOME and on Optical Coherence Tomography in Choroidal Neovascularization Subjects
NCT00884637
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Self trained subjects
No interventions assigned to this group
2
supervised trained subjects
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects diagnosed as intermediate AMD in at least one eye (in case a patient will convert during the study period he will be excluded)
* Age more than 50 years
* VA with habitual correction better than 20/60 in the study eye
* Ability to speak, read and understand instructions in English or Hebrew
* Familiar with computer usage
Exclusion Criteria
* Presence of any significant media opacity that precludes a clear view of the macular area as identified in the study eye by biomicroscopy, CFP.
* Any non-macular related ocular surgery performed within 3 months prior to study entry in the target eye
* Never been tested on the PHP device
* Participation in another study with the exclusion of AREDS study
* Patients diagnosed with geographic atrophy (GA)
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Notal Vision Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Haya Morori Katz, M.D.
Role: PRINCIPAL_INVESTIGATOR
Kaplan Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Meir Medical Center
Kfar Saba, , Israel
Kaplan Medical Center
Rehovot, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
sponsor site
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HMP-UU2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.